Superior Efficacy of Tafenoquine/Atovaquone for Babesiosis Therapy

Superior Efficacy of Tafenoquine/Atovaquone for Babesiosis Therapy

Table of Contents


Choukri Ben Mamoun, PhD

Journal of Infectious Illness (Vydyam, P., et al.) 01.03.2024 printed forward of print “Tafenoquine-Atovaquone Mixture Achieves Radical Treatment and Confers Sterile Immunity in Experimental Fashions of Human Babesiosis.” On this examine, researchers display that therapy with tafenoquine (antimalarial drug) inhibits the expansion of a number of Babesia species in vitro,  exhibits nice effectiveness in opposition to each Babesia microti and Babesia duncani in mice, and protects in opposition to deadly an infection in animals from atovaquone-sensitive and resistant of B. duncani strains.

The examine additionally discovered that eradication of illness is attained with use of mixture of tafenoquine and atovaquone with no recurrence of illness in each human babesiosis fashions. Drug therapy that resulted in elimination of B. duncani an infection in animals additionally confers immunity with subsequent exposures to this pathogen.

Mixture tafenoquine/atovaquone therapy exhibits superior efficacy of over present therapies for the therapy of human babesiosis and gives potential for protecting immunity in opposition to future Babesia infections.

NOTE: Co-Creator of this text, Choukri Ben Mamoun, offered Human Babesiosis as keynote speaker on the LDA-Columbia Lyme & Tick-Borne Convention in October 2023.


For Extra Info: 

Access to the Journal of Infectious Disease Article

Choukri Ben Mamoun, LDA/Columbia Conference 2023

Read More LDA Articles on Babesiosis

The put up Superior Efficacy of Tafenoquine/Atovaquone for Babesiosis Treatment appeared first on Lyme Disease Association.



Source link

Facebook
Twitter
LinkedIn
WhatsApp
Email

Leave a Reply

Your email address will not be published.